Skip to main content

Table 1 Associations of baseline characteristics with the outcomes among 790 ART-eligible patients.

From: Pre-treatment mortality and loss-to-follow-up in HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients eligible for antiretroviral therapy in The Gambia, West Africa

Variable

Started ART

Transferred

LTFU

Died

p-value

Total (n = 790)

510 (64.6)

26 (3.3)

136 (17.2)

118 (14.9)

 

Sex: (n = 790)

     

Male

149 (59.4)

5 (2.0)

48 (19.1)

49 (19.5)

0.025

Female

361 (67.0)

21 (3.9)

88 (16.3)

69 (12.8)

 

Age: (n = 790)

     

Median in yrs (IQR)

37 (30, 44)

35 (28, 47)

36 (29, 44)

37 (31, 45)

0.549§

<30

116 (62.7)

8 (4.3)

36 (19.5)

25 (13.5)

0.870

30 - 40

217 (66.1)

10 (3.1)

51 (15.6)

50 (15.2)

 

>40

177 (63.9)

8 (2.9)

49 (17.7)

43 (15.5)

 

HIV type: (n = 790)

     

HIV-1

419 (64.8)

18 (2.8)

114 (17.6)

96 (14.8)

0.526Ω

HIV-2

66 (64.0)

7 (6.8)

15 (14.6)

15 (14.6)

 

HIV-dual

25 (62.5)

1 (2.5)

7 (17.5)

7 (17.5)

 

CD4 count: (n = 788)

     

Median in cells/ml (IQR)

150 (80, 240)

235 (190, 290)

130 (65, 200)

95 (40, 172)

0.0001 §

<100

149 (57.8)

2 (0.8)

49 (19.0)

58 (22.4)

<0.001

≥100

361 (68.1)

24 (4.5)

87 (16.4)

58 (11.0)

 

Occupation: (n = 477)

     

Employed

161 (61.9)

9 (3.5)

45 (17.3)

45 (17.3)

0.074

Unemployed

154 (71.0)

4 (1.8)

37 (17.1)

22 (10.1)

 

WHO stage: (n = 723)

     

1 or 2

425 (64.6)

21 (3.2)

115 (17.5)

97 (14.7)

 

3 or 4

33 (50.8)

3 (4.6)

10 (15.4)

19 (29.2)

0.018

  1. Unless otherwise indicated, data are No. (%) of patients in each outcome category
  2. ‡Chi-square test
  3. Ω Fishers exact test
  4. § Kruskall-Wallis test